Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study on the Clinical Course Of Pulmonary Embolism (SCOPE)

13. juni 2016 oppdatert av: Raffaele Pesavento, University of Padova

The course of both pulmonary embolism (PE) and one of its more relevant late complications, i.e. chronic thromboembolic pulmonary hypertension (CTEPH) is still substantially unknown.

Recent evidence has shown that the incidence of CTEPH is higher than previously believed, but this has not been confirmed by other studies. A clear link between PE and CTEPH has been questioned by some experts. A great number of patients affected by PE persistently have residual chronic thromboembolic material the meaning of which is a matter of debate. The evidence sustaining a link between chronic residual PE and subsequent PE recurrences or CTEPH is insufficient.

Thus, a nationwide, multicentre, prospective cohort study was designed with the following aims:

  1. to ascertain the incidence of symptomatic CTEPH after a first episode of acute PE;
  2. to ascertain the incidence of venous thromboembolic (VTE) recurrences after a first episode of acute PE;
  3. to evaluate whether a relation exists between chronic residual PE and CTEPH
  4. to evaluate whether a relation exists between chronic residual PE and VTE recurrences;
  5. to evaluate whether a relation exists between persistent right ventricular dysfunction and CTEPH;
  6. to evaluate whether a relation exists between persistent right ventricular dysfunction and PE recurrences.

For each enrolling centre, consecutive outpatients or inpatients with an objectively diagnosed first acute PE episode are considered eligible.

Studieoversikt

Detaljert beskrivelse

All patients enrolled in the study received a diagnosis of PE by means of chest CT scan, lung scanning or pulmonary angiography. All patients should undergo an echocardiographic examination during the acute phase of PE, when this is possible. All patients will be treated according to current international guidelines and local protocols. All surviving patients will receive an echocardiographic examination after 6 weeks and 6 months. All surviving patients will receive a perfusional pulmonary scintigraphy at 6 months and be subsequently followed up every 6 months for at least 3 years.

In case of clinical suspicion of VTE recurrence a diagnostic procedure will be performed in order to confirm the recurrent VTE episode ( Chest CT scan, lung scan, Pulmonary angiography, compressive ultrasound, phlebography, vein CT scan).

In case of clinical suspicion of CTEPH, a further diagnostic workup will be performed, consisting in echocardiography, ventilation/perfusion lung scanning, multidetector chest CT scanning, and pulmonary angiography, with direct measurement of the pulmonary-artery pressure.

The extension of pulmonary embolism during the acute phase will be graded according to a standardized scoring system by local investigators while the extension of chronic residual pulmonary embolism will be graded according to a standardized scoring system ( Meyer score) by both local investigators and an independent committee. All outcome events will be centrally adjudicated by an independent committee.

All clinical data ( initial data on medical history, clinical symptoms, presence of risk factors, diagnoses, diagnostic tests results, treatment type and duration, outcome events and other) will be collected by the local investigators in an electronic medical database. Related data will be sent to the coordinating centre on a regular basis. All recruiting centres will be regularly monitored by the coordinating Centre.

Studietype

Observasjonsmessig

Registrering (Faktiske)

700

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Consecutive outpatients or inpatients with an objective diagnosis of first acute PE episode.

Beskrivelse

Inclusion Criteria:

  • Consecutive Outpatients/Inpatients with acute first episode of acute pulmonary embolism

Exclusion Criteria:

  • Pregnancy
  • Age < 18 years
  • expected survival < 2 years
  • previous episodes of VTE
  • need for anticoagulation for reasons other than VTE
  • preexisting severe cardiac or pulmonary diseases
  • preexisting diseases that could cause non thromboembolic pulmonary hypertension
  • Patients geographically inaccessible for follow up
  • Low compliance to anticoagulant therapy and planned diagnostic work-up
  • Refusal to give written informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
pulmonary embolism
Consecutive outpatients and inpatients with first episode of acute pulmonary embolism

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Incidence of chronic thromboembolic pulmonary hypertension
Tidsramme: within 3 years
within 3 years

Sekundære resultatmål

Resultatmål
Tidsramme
Incidence of recurrent venous thromboembolic events
Tidsramme: within 3 years
within 3 years

Andre resultatmål

Resultatmål
Tidsramme
Incidence of all-cause mortality
Tidsramme: within 3 years
within 3 years
Incidence of Pulmonary Embolism - related mortality
Tidsramme: within 3 years
within 3 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Raffaele Pesavento, MD, University of Padova
  • Studiestol: Paolo Prandoni, MD,PHD, University of Padova
  • Studiestol: Antonio Pagnan, MD, University of Padova
  • Studiestol: Antonio Palla, MD, University of Pisa, Italy
  • Studiestol: Vittorio Pengo, MD, University of Padova
  • Studiestol: Franco Piovella, MD, University of Pavia - Italy

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2008

Primær fullføring (Faktiske)

1. mai 2014

Studiet fullført (Faktiske)

1. juli 2014

Datoer for studieregistrering

Først innsendt

30. januar 2013

Først innsendt som oppfylte QC-kriteriene

30. januar 2013

Først lagt ut (Anslag)

1. februar 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

14. juni 2016

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. juni 2016

Sist bekreftet

1. juni 2016

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

3
Abonnere